BPC-157 vs TB-500
BPC-157 and TB-500 are two of the most commonly discussed recovery peptides. While they are both explored for tissue repair, they work through different mechanisms and have different evidence profiles. Understanding these differences can help inform conversations with your clinician about which might be more appropriate for your situation.
BPC-157
A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.
TB-500
A synthetic version of the active region of thymosin beta-4, widely used for tissue repair, wound healing, and recovery from injuries.
| Category | BPC-157 | TB-500 |
|---|---|---|
| Primary Mechanism | Angiogenesis, growth factor modulation, NO system | Actin regulation, cell migration, anti-inflammation |
| Evidence Depth | Extensive animal data, very limited human trials | Moderate animal data, limited human trials |
| Common Discussion Context | Tendon/ligament injuries, gut healing, localized repair | Systemic recovery, wound healing, cardiac repair |
| Route of Administration | Subcutaneous (near injury site) or oral | Subcutaneous or intramuscular |
| Safety Profile | Favorable in animal studies, limited human data | Limited data, theoretical cancer concerns |
| Beginner Accessibility | Often considered more beginner-friendly | Typically discussed for more experienced users |
Summary
The key difference between BPC-157 and TB-500 lies in their mechanisms. BPC-157 primarily promotes healing through angiogenesis (new blood vessel formation) and growth factor modulation, making it particularly discussed for localized injuries. TB-500 works through actin regulation and cell migration, potentially offering more systemic repair support. In practice, many practitioners don't choose between them — they use both together. The BPC-157 + TB-500 combination, known as the "Wolverine Stack," is the most popular peptide recovery protocol. BPC-157 drives local vascularization while TB-500 facilitates systemic cell migration, creating complementary repair pathways. Neither compound has robust human clinical trial data individually, and the combination rationale is mechanistic rather than clinically proven. Both should be used under clinician guidance.
These peptides are often used together. See our stack profiles for combination details.